文献速递消化与肝胆胰病理

TM4SF5介导的SIRT1调节与代谢信号在非酒精性脂肪性肝炎进展中的差异作用

Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression.
PubMed 文献 · J Pathol · 2020-10-22

该研究利用转基因与敲除小鼠、饮食或药物处理小鼠、体外原代细胞及人肝组织,探究TM4SF5在非酒精性脂肪性肝炎(NASH)进展中的作用。结果显示TM4SF5过表达小鼠呈年龄依赖性脂肪变与NASH,早期伴SIRT1降低、SREBPs升高及SOCS1/3上调致STAT3失活,后期经趋化因子促SIRT1表达与STAT3活化,促进ECM产生和纤维化进展。

要点

  • TM4SF5过表达小鼠年龄依赖性出现脂肪变与NASH。
  • 早期SIRT1降低、SREBPs升高、SOCS1/3上调致STAT3失活。
  • 后期趋化因子促SIRT1与STAT3活化,驱动ECM产生和纤维化。

核心结论

  • TM4SF5介导的SIRT1、SREBPs与SOCS/STAT3信号通路促进NASH进展。
  • TM4SF5及其下游效应器可能成为治疗非酒精性脂肪性肝病的靶点。

研究设计与样本

  • 研究使用转基因与敲除小鼠、饮食或药物处理小鼠、体外原代细胞及人肝组织。

主要发现

  • TM4SF5过表达小鼠呈年龄依赖性非酒精性脂肪变与NASH。
  • 早期TM4SF5阳性肝细胞脂质积聚,SIRT1降低,SREBPs升高,SOCS1/3上调致STAT3失活。
  • 老年小鼠中TM4SF5促炎症因子诱导、SIRT1表达与STAT3活性,SOCS或SREBP水平不变,活化STAT3介导ECM产生。
  • TM4SF5相关趋化因子增加促SIRT1表达及向纤维化NASH进展,抑制CCL20减少免疫细胞浸润与ECM产生。
  • 纤维化NASH肝中TM4SF5介导STAT3活化增加胶原I与层粘连蛋白γ2,抑制两者降低SIRT1与活化STAT3但不改变SREBP1或SOCS,并消除CCl4介导的小鼠肝损伤。

临床怎么用

  • TM4SF5及其下游效应器可能作为治疗非酒精性脂肪性肝病的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease is a chronic condition involving steatosis, steatohepatitis and fibrosis, and its progression remains unclear. Although the tetraspanin transmembrane 4 L six family member 5 (TM4SF5) is involved in hepatic fibrosis and cancer, its role in nonalcoholic steatohepatitis (NASH) progression is unknown. We investigated the contribution of TM4SF5 to liver pathology using transgenic and KO mice, diet- or drug-treated mice, in vitro primary cells, and in human tissue. TM4SF5-overexpressing mice exhibited nonalcoholic steatosis and NASH in an age-dependent manner. Initially, TM4SF5-positive hepatocytes and liver tissue exhibited lipid accumulation, decreased Sirtuin 1 (SIRT1), increased sterol regulatory-element binding proteins (SREBPs) and inactive STAT3 via suppressor of cytokine signaling (SOCS)1/3 upregulation. In older mice, TM4SF5 promoted inflammatory factor induction, SIRT1 expression and STAT3 activity, but did not change SOCS or SREBP levels, leading to active STAT3-mediated ECM production for NASH progression. A TM4SF5-associated increase in chemokines promoted SIRT1 expression and progression to NASH with fibrosis. Suppression of the chemokine CCL20 reduced immune cell infiltration and ECM production. Liver tissue from high-fat diet- or CCl4 -treated mice and human patients exhibited TM4SF5-dependent steatotic or steatohepatitic livers with links between TM4SF5-mediated SIRT1 modulation and SREBP or SOCS/STAT3 signaling axes. TM4SF5-mediated STAT3 activation in fibrotic NASH livers increased collagen I and laminin γ2. Both collagen I α1 and laminin γ2 suppression resulted in reduced SIRT1 and active STAT3, but no change in SREBP1 or SOCS, and abolished CCl4 -mediated mouse liver damage. TM4SF5-mediated signaling pathways that involve SIRT1, SREBPs and SOCS/STAT3 promoted progression to NASH. Therefore, TM4SF5 and its downstream effectors may be promising therapeutic targets to treat nonalcoholic fatty liver disease. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Ryu J, Kim E, Kang MK, et al. Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression. J Pathol. 2020. PMID: 32918742. doi:10.1002/path.5548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。